164 related articles for article (PubMed ID: 37578479)
1. Synthesis and Radiolabeling of Glu-Urea-Lys with
Hatamabadi D; Joukar S; Shakeri P; Balalaie S; Yazdani A; Khoramjouy M; Mazidi SM; Kobarfard F; Mosayebnia M; Bozorgchami N; Ahmadi M; Ayyoubzadeh SM; Shahhosseini S
Cancer Biother Radiopharm; 2023 Sep; 38(7):486-496. PubMed ID: 37578479
[No Abstract] [Full Text] [Related]
2. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S
Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
[TBL] [Abstract][Full Text] [Related]
3. Clinical translation of a PSMA inhibitor for
Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
[TBL] [Abstract][Full Text] [Related]
4. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and SAR of ⁹⁹mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates.
Lu G; Maresca KP; Hillier SM; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
Bioorg Med Chem Lett; 2013 Mar; 23(5):1557-63. PubMed ID: 23333070
[TBL] [Abstract][Full Text] [Related]
6.
Xu X; Zhang J; Hu S; He S; Bao X; Ma G; Luo J; Cheng J; Zhang Y
Nucl Med Biol; 2017 May; 48():69-75. PubMed ID: 28273495
[TBL] [Abstract][Full Text] [Related]
7. Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction.
Hensbergen AW; Buckle T; van Willigen DM; Schottelius M; Welling MM; van der Wijk FA; Maurer T; van der Poel HG; van der Pluijm G; van Weerden WM; Wester HJ; van Leeuwen FWB
J Nucl Med; 2020 Feb; 61(2):234-241. PubMed ID: 31481575
[TBL] [Abstract][Full Text] [Related]
8. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
Ray Banerjee S; Pullambhatla M; Foss CA; Falk A; Byun Y; Nimmagadda S; Mease RC; Pomper MG
J Med Chem; 2013 Aug; 56(15):6108-21. PubMed ID: 23799782
[TBL] [Abstract][Full Text] [Related]
9. Preparation and Biological Evaluation of [
Xiao D; Duan X; Gan Q; Zhang X; Zhang J
Molecules; 2020 Nov; 25(23):. PubMed ID: 33256058
[TBL] [Abstract][Full Text] [Related]
10. Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.
Kimura H; Sampei S; Matsuoka D; Harada N; Watanabe H; Arimitsu K; Ono M; Saji H
Bioorg Med Chem; 2016 May; 24(10):2251-6. PubMed ID: 27073053
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Evaluation of
Lu K; Zhang C; Zhang Z; Kuo HT; Colpo N; Bénard F; Lin KS
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446782
[TBL] [Abstract][Full Text] [Related]
12. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of new mixed "2 + 1" Re,
Shegani A; Ischyropoulou M; Roupa I; Kiritsis C; Makrypidi K; Papasavva A; Raptopoulou C; Psycharis V; Hennkens HM; Pelecanou M; Papadopoulos MS; Pirmettis I
Bioorg Med Chem; 2021 Oct; 47():116373. PubMed ID: 34467870
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).
Banerjee SR; Foss CA; Castanares M; Mease RC; Byun Y; Fox JJ; Hilton J; Lupold SE; Kozikowski AP; Pomper MG
J Med Chem; 2008 Aug; 51(15):4504-17. PubMed ID: 18637669
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a New
Farahani AM; Maleki F; Sadeghzadeh N; Abediankenari S; Abedi SM; Erfani M
Anticancer Agents Med Chem; 2020; 20(14):1695-1703. PubMed ID: 32560611
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
[TBL] [Abstract][Full Text] [Related]
17. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
19. p-NCS-Bn-NODAGA as a bifunctional chelator for radiolabeling with the
H A Kankanamalage P; Hoerres R; Ho KV; Anderson CJ; Gallazzi F; Hennkens HM
Nucl Med Biol; 2022; 108-109():1-9. PubMed ID: 35144046
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of a Novel High-Affinity Radioligand [
Bezverkhniaia E; Kanellopoulos P; Abouzayed A; Larkina M; Oroujeni M; Vorobyeva A; Rosenström U; Tolmachev V; Orlova A
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
